Although recurrent oncogenic lesions, most notably KRAS substitutions at G12 (G12D/V/R) in nearly 90% of cases [3] and TP53 (identified in about 77%) [4], represent prototypical tumor-specific antigens (TSAs), efforts to therapeutically target them have achieved limited success. The gene discussed is KRAS; the disease is neoplasm.